SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 1, 2023
(Exact name of registrant as specified in its charter)
|Delaware|| ||001-38701|| ||26-2216351|
|(State or other jurisdiction of|
incorporation or organization)
| ||(I.R.S. Employer|
471 El Camino Real
Santa Clara, CA 95050
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, include area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|Securities registered pursuant to Section 12(b) of the Act:
|Title of each class ||Trading Symbol(s) ||Name of each exchange on which registered |
|Common Stock, par value $0.0001 per share||SIBN||The Nasdaq Global Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On May 1, 2023, SI-BONE, Inc. (the "Company") issued a press release (the “Press Release”) announcing results for the quarter ended March 31, 2023. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated by reference herein.
The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| || ||SI-BONE, INC.|
| || || |
|Date:||May 1, 2023||By:||/s/ Anshul Maheshwari|
| || || ||Anshul Maheshwari|
|Chief Financial Officer|
| || || ||(Principal Financial and Accounting Officer)|
SI-BONE, Inc. Reports Financial Results for the First Quarter 2023 and Increases Annual Guidance
Annual guidance increased to $128 million - $131 million, implying annual growth of 20%-23%
SANTA CLARA, Calif. May 1, 2023 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2023.
•Record worldwide revenue of $32.7 million for the first quarter 2023, representing approximately 46% increase over the corresponding period in 2022
•Record U.S. revenue of $30.5 million for the first quarter 2023, representing approximately 50% increase over the corresponding period in 2022
•Gross margin of 82% for the first quarter 2023
•Over 950 U.S. active surgeons in the first quarter 2023, representing approximately 40% growth over the corresponding period in 2022
•Extended first-generation iFuse patent protection to December 2025, with iFuse-3D patent coverage to September 2035
•Celebrating our 15-year commitment to pioneering solutions for sacropelvic conditions through the industry's most innovative portfolio, with over 80,000 procedures completed by over 3,000 surgeons worldwide
“I am thrilled with our stellar start to 2023, as record procedure demand in the quarter allowed us to deliver approximately 50% U.S. revenue growth and achieve significant operating leverage,” said Laura Francis, Chief Executive Officer of SI-BONE. “The continued trend of accelerating revenue growth over the last several quarters is a testament to the perseverance and grit of our dedicated team members and the strong reception for our expanded portfolio of solutions. With yet another quarter of record increase in our active surgeon base combined with the favorable reimbursement framework, we are at an inflection in the business. These trends solidify my conviction in our ability to deliver strong and sustainable growth and drive operating leverage as we progress through the year."
First Quarter 2023 Financial Results
Worldwide revenue was $32.7 million in the first quarter 2023, a 46% increase from $22.4 million in the corresponding period in 2022. U.S. revenue for the first quarter 2023 was $30.5 million, a 50% increase from $20.4 million in the corresponding period in 2022. International revenue for the first quarter 2023 was $2.3 million, a 9% increase from $2.1 million in the corresponding period in 2022.
Gross margin was 82% for the first quarter 2023, as compared to 87% in the corresponding period in 2022. Gross margin in the first quarter 2023 was impacted by procedure and product mix given the higher total costs of the newly launched implants. Gross margin also includes the impact of higher depreciation from instrument trays to support the growth of the business, depreciation associated with our second facility in Santa Clara, and higher freight costs.
Operating expenses increased 5% to $38.1 million in the first quarter 2023, as compared to $36.3 million in the corresponding period in 2022. The increase was primarily driven by increase in sales commission and stock-based compensation from higher headcount, and increase in travel costs.
Operating loss improved by 33% to $11.3 million in the first quarter 2023, as compared to an operating loss of $16.9 million in the corresponding period in 2022.
Net loss was $11.1 million, or $0.32 per diluted share for the first quarter 2023, as compared to a net loss of $17.4 million, or $0.52 per diluted share in the corresponding period in 2022.
Adjusted EBITDA loss was negative $3.9 million, in the first quarter 2023, as compared to an adjusted EBITDA loss of negative $10.7 million, in the corresponding period in 2022.
Cash and marketable securities were $86.0 million and borrowings were $35.9 million as of March 31, 2023.
2023 Updated Financial Guidance
Based on the first quarter of 2023 results, SI-BONE is updating its 2023 worldwide revenue guidance to be in the range of $128 million to $131 million, implying growth of approximately 20% to 23%. SI-BONE is maintaining its guidance for fiscal year 2023 gross margin of approximately 80% and improving adjusted EBITDA loss.
SI-BONE will host a conference call to discuss the first quarter 2023 financial results after market close on Monday, May 1, 2023 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/ev5vig6x. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
About SI-BONE, Inc.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 80,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
SI-BONE is a registered trademark of SI-BONE, Inc. ©2023 SI-BONE, Inc. All Rights Reserved.
Forward Looking Statements
The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, contained in this press release are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's devices. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filings on Form 10-K and Form 10-Q, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.
Use of Non-GAAP Financial Measures
SI-BONE uses adjusted EBITDA, a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation. SI-BONE believes the presentation of adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.
Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease SI-BONE's reported results of operations, management strongly encourages investors to review, when they become available, the company's consolidated financial statements and publicly filed reports in their entirety. The company's definition of adjusted EBITDA may differ from similarly titled measures used by others.
Sr. Director, FP&A and Investor Relations
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
|Three Months Ended|
|$||32,708 ||$||22,439 |
Cost of goods sold
|5,924 ||2,983 |
|Gross profit||26,784 ||19,456 |
|Sales and marketing||27,313 ||25,605 |
|Research and development||3,291 ||3,580 |
|General and administrative||7,473 ||7,139 |
Total operating expenses
|38,077 ||36,324 |
Loss from operations
Interest and other income (expense), net:
|Interest income||932 ||73 |
|Other income (expense), net||74 ||(54)|
Net loss per share, basic and diluted
Weighted-average number of common shares used to compute basic and diluted net loss per share
|34,916,106 ||33,792,326 |
CONDENSED CONSOLIDATED BALANCE SHEETS
|March 31, 2023||December 31, 2022|
|Cash and cash equivalents||$||22,969 ||$||20,717 |
|Short-term investments||62,997 ||76,573 |
|Accounts receivable, net ||22,600 ||20,674 |
|Inventory||17,790 ||17,282 |
|Prepaid expenses and other current assets||2,045 ||2,365 |
|Total current assets||128,401 ||137,611 |
|Property and equipment, net||16,629 ||15,564 |
|Operating lease right-of-use assets||3,672 ||4,002 |
|Other non-current assets||374 ||375 |
|TOTAL ASSETS ||$||149,076 ||$||157,552 |
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$||5,331 ||$||6,279 |
|Accrued liabilities and other||9,896 ||13,511 |
|Operating lease liabilities, current portion||1,401 ||1,388 |
|Total current liabilities||16,628 ||21,178 |
|Long-term borrowings||35,938 ||35,171 |
|Operating lease liabilities, net of current portion||2,525 ||2,871 |
|Other long-term liabilities||26 ||30 |
|TOTAL LIABILITIES||55,117 ||59,250 |
|Common stock and additional paid-in capital||461,889 ||455,175 |
|Accumulated other comprehensive income||300 ||232 |
|TOTAL STOCKHOLDERS’ EQUITY||93,959 ||98,302 |
|TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY||$||149,076 ||$||157,552 |
RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA
|Three Months Ended March 31,|
|Interest expense||838 ||561 |
|Depreciation and amortization||1,086 ||713 |
|Stock-based compensation||6,194 ||5,507 |